| Title | Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. |
| Publication Type | Journal Article |
| Year of Publication | 2015 |
| Authors | Boi M, Zucca E, Inghirami G, Bertoni F |
| Journal | Br J Haematol |
| Volume | 168 |
| Issue | 6 |
| Pagination | 771-83 |
| Date Published | 2015 Mar |
| ISSN | 1365-2141 |
| Keywords | Anaplastic Lymphoma Kinase, Antineoplastic Agents, Crizotinib, Humans, Immunophenotyping, Lymphoma, Large-Cell, Anaplastic, Molecular Targeted Therapy, Protein Kinase Inhibitors, Pyrazoles, Pyridines, Receptor Protein-Tyrosine Kinases, Signal Transduction, Translocation, Genetic |
| Abstract | The currently used 2008 World Health Organization classification recognizes two types of systemic anaplastic large T cell lymphoma according to ALK protein expression in tumour cells. First, the 'anaplastic large cell lymphoma, ALK positive' (ALK(+) ALCL) that is characterized by the presence of ALK gene rearrangements and consequent ALK protein expression, and, second, the 'anaplastic large cell lymphoma, ALK negative' (ALK(-) ALCL) that is a provisional entity lacking ALK protein expression but cannot be distinguished morphologically from ALK(+) ALCL. In this review we summarize the current knowledge on the genetic lesions and biological features that underlie the pathogenesis of ALK(+) and the ALK(-) ALCL and that can lead to the use of targeted anti-cancer agents. |
| DOI | 10.1111/bjh.13265 |
| Alternate Journal | Br J Haematol |
| PubMed ID | 25559471 |
Related Faculty:
Giorgio Inghirami, M.D.